TG Therapeutics, Inc. (NASDAQ:TGTX) stock is trading higher on Wednesday after the company announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials, evaluating BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis.

The Details: The data was shared at the 2024 European Committee for Treatment and Research in Multiple Sclerosis annual meeting, with the presentations also accessible online.

The data indicated that continued use of BRIUMVI resulted in decreasing annualized relapse rates. Specifically, at year three, the annualized release rate was 3.2%, but at year five the annualized relapse rate was 2%.

Furthermore, the data showed that after five years of continuous treatment 17% of patients achieved confirmed disability improvement for at least 24 weeks. Eight percent of patients experienced confirmed disability progression for at least 24 weeks following five years of treatment.

In addition, the safety profile of BRIUMVI remained stable over five years of continuous treatment.

"These data demonstrate that patients treated with BRIUMVI for up to 5 years had sustained clinical benefit, including further reductions in the risk of relapse in later years of treatment and an impressively low rate of confirmed disability progression," said CEO and chairman of TG Therapeutics Michael Weiss.

TGTX Price Action: At the time of publication, TG Therapeutics stock is moving 1.52% higher at $25.46 per data from Benzinga Pro.

Image: Photo by roberto-sorin for Unsplash